Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography

• Published in: Biomedicines 2024-05, Vol.12 (5), p.1113
• Main Authors: Kim, Narae, Cho, Jin-Man, Yang, In-Ho
• Format: Article
• Language: English
• Subjects: acute coronary syndrome; Acute coronary syndromes; Angina; Angina pectoris; Angiography; Anticholesteremic agents; Atherosclerosis; Cardiac patients; Cardiology; Cardiovascular disease; Cardiovascular diseases; Care and treatment; Case reports; Cholesterol; coronary angiography; Coronary artery disease; Coronary heart disease; Coronary vessels; Diseases; evolocumab; Genetic aspects; Heart diseases; High density lipoprotein; Hypercholesterolemia; Kexin; lipid-lowering therapy; Lipids; Low density lipoprotein; Low density lipoproteins; Medical imaging; optical coherence tomography; Patients; Prevention; Proprotein convertases; Proteins; Relapse; Risk groups; Statins; Stents; Subtilisin; Tomography
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12051113

In patients with acute coronary syndrome (ACS), lipid-lowering therapy plays an important role in the prevention of the recurrence of cardiovascular disease. Recent guidelines recommend the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with ACS if their low-density lipoprotein cholesterol (LDL-C) levels are not adequately controlled with statins and ezetimibe. Based on this, we report a case in which administering a PCSK9 inhibitor successfully lowered the patient's LDL-C level to the target level and managed the coronary artery disease (CAD) recurrence. A 39-year-old man who was taking statins presented to the hospital with chest pain and was diagnosed with unstable angina. He started taking maximum doses of statins and ezetimibe to lower his LDL-C. However, the patient's unstable angina recurred 1 year later, and a de novo lesion with plaque rupture was demonstrated via coronary angiography. The LDL-C failed to reach the target level despite maintaining the maximum dose of statin and ezetimibe. Accordingly, evolocumab was initiated in addition to rosuvastatin/ezetimibe 20/10 mg daily. Subsequently, coronary angiography was performed twice, and on follow-up, the patient remained free of CAD recurrence. This case highlights the efficacy of lipid-lowering therapy with evolocumab in high-risk patients with repeated ACS.